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focal segmental glomerulosclerosis (FSGS) and not in patients
with other glomerular diseases. The authors proposed that
high serum suPAR (X3000 pg/ml) is speciﬁc for primary
FSGS. However, in many of their patients with suspected
primary FSGS, serum albumin was normal or unknown. The
absence of hypoalbuminemia despite heavy proteinuria
suggests that FSGS is due to hyperﬁltration rather than
primary FSGS.2 It is also unknown whether suPAR is
associated with response to corticosteroids. To determine
the value of suPAR in routine clinical practice we measured
suPAR concentration in sera of adult patients with idiopathic
(primary) FSGS (n¼ 11), secondary FSGS (hyperﬁltration
n¼ 3, familial n¼ 2), and minimal change disease (MCD; n¼ 7)
with the Quantikine Human suPAR Immunoassay (R&D
Systems, Minneapolis, MN). Median serum suPAR concentra-
tion was not different between idiopathic FSGS (2392 pg/ml),
secondary FSGS (2716 pg/ml), and MCD (2482 pg/ml),
nor did it predict steroid responsiveness in patients with
idiopathic FSGS/MCD (Figure 1). We found a negative cor-
relation between suPAR and estimated glomerular ﬁltration
rate Modiﬁcation of Diet in Renal Disease (MDRD)-6
(Figure 2). In conclusion, suPAR concentration is not a
speciﬁc marker for idiopathic FSGS in this study and it does
not reliably predict response to treatment. Although our data
indicate that for the individual patient suPAR is not a reliable
marker, the small size of our study does not allow deﬁnite
conclusions on the role of suPAR in FSGS. A larger study is
needed to clarify this issue.
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The contribution of chronic kidney
disease to the global burden of
major noncommunicable diseases
To the Editor: We have read the report of the ISN Global
Outreach Programme,1 which conﬁrms that, for the less
developed countries compared with the more developed ones,
chronic glomerulonephritis (GN) and not diabetic nephrop-
athy (DiabNx) is still the leading cause of end-stage renal
failure (ESRF).
The more developed Asian countries including Singapore,
Malaysia, India, and China are now faced with the burden
of diseases associated with lifestyle changes, such as diabetes
mellitus and obesity. Despite the decreasing prevalence of
chronic kidney disease-associated proteinuria due to chronic
GN and hypertensive nephrosclerosis, as a result of programs
to control and retard progression in these two diseases, the
dilemma of the epidemic proportion of DiabNx is far from
being contained. In Singapore, the incidence of DiabNx as a
cause of ESRF in 1983 was 17%, in 2004 it was 58%, and in
2008 it further rose to 63% in patients initiating dialysis.2
However, the incidence of ESRF has stabilized over the past
3 years. In 1975, it was 90 per million population (p.m.p.),
with a progressive increase to peak at 264 p.m.p. in 2007. Over
the past 3 years (2006–2008), it has remained at 238, 264, and
245 p.m.p. (ever start dialysis) or 207, 212, and 211 p.m.p.
(survive 90 days of dialysis).2
Angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers (ACEIs/ARBs) have been around for years,
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Figure 1 | Serum suPAR concentrations in patients with
idiopathic focal segmental glomerulosclerosis (FSGS),
minimal change disease (MCD) and secondary FSGS. Median
suPAR concentration is indicated by the horizontal line.
n, steroid-sensitive (complete remission); m, steroid-resistant
(no remission); , no immunosuppressive therapy.
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Figure 2 |Correlation analysis of suPAR with estimated
glomerular filtration rate (eGFR) MDRD-6. Spearman’s rho
0.46, P¼ 0.03.
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but the incidence of ESRF due to DiabNx has not stabilized.3
There is also the growing concern that long-term use of
ACEIs/ARBs could promote renal ﬁbrosis.4 This may be one
explanation of why the incidence of ESRF due to DiabNx has
not plateaued despite the stabilization of the incidence of
ESRF. Perhaps the time has come for ISN experts to focus on
the burden of ESRF due to DiabNx in these countries.
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